Skip to main
RPRX
RPRX logo

Royalty Pharma (RPRX) Stock Forecast & Price Target

Royalty Pharma (RPRX) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 65%
Buy 24%
Hold 12%
Sell 0%
Strong Sell 0%
Royalty Pharma (RPRX) has been analyzed by 17 analysts, with a consensus rating of Buy. 65% of analysts recommend a Strong Buy, 24% recommend Buy, 12% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Royalty Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Royalty Pharma (RPRX) Forecast

Analysts have given Royalty Pharma (RPRX) a Buy based on their latest research and market trends.

According to 17 analysts, Royalty Pharma (RPRX) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Royalty Pharma (RPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.